Pregnancy Thromboprophylaxis
 

Pregnancy Thromboprophylaxis

   

Thromboprophylaxis in pregnancy and the puerperium

Home
Pregnancy Calendar
Pregnancy
Pregnancy and Childbirth
Pregnancy and Childbirth
Pregnancy and Childbirth
Pregnancy and Childbirth
Pregnancy and Childbirth
Pregnancy Date Calculator
Symptoms & Signs
Pregnancy - Antenatal Care
Pregnancy
Gestational Age
Gestational Age Intro
Morning Sickness
Smoking
Obesity
Diabetes in Pregnancy
Gestational Diabetes
Liver
Infections
Teen Pregnancy
Depression in Pregnancy
Headache
PET Definitions
Aetiology - Pre-Eclampsia and Eclampsia
Antepartum Haemorrhage
Intrautrine Growth Restriction - IUGR
Breech Presentation
Twins
Teenage Pregnancy.
Thromboprophylaxis in pregnancy and the puerperium
Premature Labour
Post-Maturity
Induction Of Labour
Planned Delivery
Water Birth
Operative Vaginal Delivery-Forceps Delivery
Vacuum Extraction Delivery
Shoulder Dystocia
Caesarean Section
Obstetric Emergencies
Puerperium
Post-Partum Haemorrhage
Uterine Rupture
Childbirth
Perinatal Mortality
Breast Feeding
 

PREGNANCY

THROMBOPROPHYLAXIS

 

Agents for Thromboprophylaxis

 

 

Low molecular weight heparin

 

 

 

N Engl J Med. 1995 May 18;332(20):1330-5.

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG.

Department of Pathology, McMaster University, Hamilton, Ontario, Canada.

BACKGROUND. Heparin-induced thrombocytopenia, defined by the presence of heparin-dependent IgG antibodies, typically occurs five or more days after the start of heparin therapy and can be complicated by thrombotic events. The frequency of heparin-induced thrombocytopenia and of heparin-dependent IgG antibodies, as well as the relative risk of each in patients given low-molecular-weight heparin, is unknown. METHODS. We obtained daily platelet counts in 665 patients in a randomized, double-blind clinical trial comparing unfractionated heparin with low-molecular-weight heparin as prophylaxis after hip surgery. Heparin-induced thrombocytopenia was defined as a decrease in the platelet count below 150,000 per cubic millimeter that began five or more days after the start of heparin therapy, and a positive test for heparin-dependent IgG antibodies. We also tested a representative subgroup of 387 patients for heparin-dependent IgG antibodies regardless of their platelet counts. RESULTS. Heparin-induced thrombocytopenia occurred in 9 of 332 patients who received unfractionated heparin and in none of 333 patients who received low-molecular-weight heparin (2.7 percent vs. 0 percent; P = 0.0018). Eight of the 9 patients with heparin-induced thrombocytopenia also had one or more thrombotic events (venous in 7 and arterial in 1), as compared with 117 of 656 patients without heparin-induced thrombocytopenia (88.9 percent vs. 17.8 percent; odds ratio, 36.9; 95 percent confidence interval, 4.8 to 1638; P < 0.001). In the subgroup of 387 patients, the frequency of heparin-dependent IgG antibodies was higher among patients who received unfractionated heparin (7.8 percent, vs. 2.2 percent among patients who received low-molecular-weight heparin; P = 0.02). CONCLUSIONS. Heparin-induced thrombocytopenia, associated thrombotic events, and heparin-dependent IgG antibodies are more common in patients treated with unfractionated heparin than in those treated with low-molecular-weight heparin.

 

 

 Back Home Up Next